MedTrace Logo

Glutaminergic Transmission in Autism : Molecular Imaging Exploration

NCT02719951 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2025-12-31

No results posted yet for this study

Summary

Glutamatergic transmission exploration using PET (Positron Emission Tomography) imaging in autism compared to Fragile-X Syndrome ( FXS) and Healthy Volunteers

Conditions

  • Autism
  • Fragile-X Syndrome (FXS)
  • Healthy Volunteers

Interventions

DRUG

[18F]FPEB PET imaging

PET exam

OTHER

Biological samples

blood sample and urine sample

OTHER

MRI

MRI exam

Sponsors & Collaborators

  • University Hospital, Tours

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2018-11-15
Completion
2019-05-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02719951 on ClinicalTrials.gov